Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
IPO Year: 2014
Exchange: NASDAQ
Website: biocept.com
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (NASDAQ:PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord. CNSide is Biocept's proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration p
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Biocept
Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers.
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update. "Biocept's primary focus is establishing our proprietary cerebrospinal fluid assay CNSide™ as standard of care. We continue to diligently work towards submission to the National Comprehensive Cancer Network® (NCCN®) for consideration to include CNSide in their standard-of-care guidelines. We believe securing this status will broaden physician adoption and support reimbursement that reflects our test's value in clinical decision-making," said Antonino Morales, Biocept President and C
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company") announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept extend their deepest condolences to the Wilson family and express their gratitude for her many contributions to Biocept. Ms. Wilson was appointed to Biocept's Board in 2009 and served at various times as Lead Independent Director and as Chair. Most recently, in addition to her role as Board Chair, she was a member of the Audit, Compensation, and Science and Technology Committees. "It is with deep sadness that we announce Faye's passing," said Antonino Morales, Biocept President and CEO. "I had the gr
Samuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer,
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept's discussion will be hosted by Maxim Group Senior Research Analyst Michael Okunewitch. Registration information to become an M-Vest member for access to the live and archived presentation webcast is posted to Events & Presentations section of the Biocept website. About M-Vest M-Vest is a division of Maxim Group LLC that serves to allows investors access to investment opportu
Real-world retrospective study showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago showing the ability of CNSide™ to detect rates of leptomeningeal metastases (LM) compared with standard CSF cytology from lumbar puncture. The poster, titled "Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide compared to standard cytology," was p
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share (or pre-funded warrant in lieu thereof) and an accompanying warrant to purchase two shares of common stock. The warrants will have a per share exercise price of $4.25, are exercisable immediately, will expire five years from the date of issuance and contain an alternative cashless exercise provisi
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte
Samuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer,
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept's Audit Committee. "Quyen's extensive financial experience leading accounting and finance departments, and overseeing technical accounting, budgeting and forecasting, financial modeling, cash management and SEC reporting, make her a valuable addition to our Board and its Audit Committee," said Samuel D. Riccitelli
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the "Notice") on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising Biocept that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the "Rule") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the "Form 10-Q") in a timely manner. The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). Biocept previo
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP ("RSM") as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th straight year by Accounting Today. RSM replaces Mayer Hoffman McCann P.C. ("MHM"), which notified the company on April 7, 2022 of its decision to decline to stand for re-appointment as the company's independent registered public accounting firm. The decision by MHM was not the result of any disagreement with the company. MHM's audit reports on the company
Industry veteran to oversee operations for the company and its CNSide™ cerebrospinal fluid assay to aid in the management of patients with metastatic brain cancers Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Philippe Marchand, Ph.D., to the position of Chief Operating Officer, effective today. Dr. Marchand will be responsible for advancing the company's strategic and operational objectives, including all laboratory operations of its CNSide cerebrospinal fluid assay, which helps physicians better detect and manage treatment of patients with metastatic cancers involving the central nervous system. "Biocept is excited t
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall, and Antonino Morales as Interim Chief Financial Officer, succeeding Timothy C. Kennedy. Biocept also named M. Faye Wilson as Lead Independent Director of the company's Board of Directors. Mr. Riccitelli remains Chair of the Board. "I am grateful and excited to see Sam and Antonino stepping into their interim roles at a time when Biocept is fulfilling such an important mission for our current COVID-19 testing clients and I am even more excited about what their le
New York, March 02, 2021 (GLOBE NEWSWIRE) -- - Energy Fuels Inc (NYSEAMERICAN:UUUU) (TSE:EFR) signs deal with Neo Performance Materials to launch rare earths production program in US and Europe click here - Tartisan Nickel Corp (CSE:TN) (OTCMKTS:TTSRF) (FRA:8TA) poised for geophysical survey at flagship Kenbridge nickel-copper-cobalt project click here - Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) says it received 'positive' results from its Maximum Tolerated Dosage study of AME-1 click here - Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) (FRA:P731) doubles fiscal 3Q revenue to record C$31.5M click here - Q BioMed Inc (OTCQB:QBI